9/21/2020 ViewSpecialArticleDetail

Q Manuscript Status...



## INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

ISSN

0975-2366

IJPR INCLUDED IN UGC-APPROVED LIST OF JOURNALS - REF. NO. IS SL. NO. 4812 & J. NO. 63703

Published by : Advanced Scientific Research

Home About Us Editorial Board Instruction to Authors Current Issue Article In Press Table Of Contents

CURRENT ISSUE

No Data found.

ARTICLE IN PRESS

No Data found

ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)



Click here to Download

IJPR 9[3] JULY -SEPTEMBER 2017 SPECIAL ISSUE

July - September 9[3] 2017

Click to download

## **Article Detail**

Insilico approaches to demonstrate uzarigenin and calotropagenin as potential carbonic anhydrase II (CAII) inhibitors

Author: VIKRAM PARTHASARATHY, ACHUTHAN RAGHAVA MENON, BASAVARAJ

DEVARANAVADAGI

Abstract: Background: Inhibition studies on carbonic anhydrase II (CAII) (EC 4.2.1.1) activity are

gaining attention due to their immense therapeutic application in the treatment of cancer, and obesity. Clinically used CAII inhibitors (CAIs), such as acetazolamide, and brinzolamide produce undesirable side effects like depression, and nausea. So non-toxic and natural CAI are being researched with special interest. Steroids such as bile acids, steroidal sulfamates, and sex hormones have previously been shown to significantly inhibit CAII activity. In the current insilico study, cardiotonic steroids (uzarigenin and calotropagenin) have been investigated as possible CAII inhibitors. Objective: To evaluate uzarigenin and calotropagenin as potential inhibitors of carbonic anhydrase II (CAII) activity, using insilico methods Methods and materials: Reverse pharmacophore screening and inverse docking of ligands was performed to identify potential targets. The results were validated by docking study. The binding affinity and interactions of docked ligands viz, uzarigenin, calotropagenin, acetazolamide (standard) and cholic acid (positive control) with CAII macromolecule, was comparatively analyzed. MMPBSA calculation of protein ligand complex were computed to determine the strength of binding.

National Institute of Science Communication And Information Resources, CSIR





ONLINE SUBMISSION

Click here for Online Submission


ADMET analysis was conducted to ascertain drug like properties of ligands. Results and conclusion: Uzarigenin (Ki= -7.6 kcal/mol) and calotropagenin (Ki= -7.9 kcal/mol), by virtue of their interaction with catalytically important residues (Phe130, Ile91, Gln92), good fit score (2.82, and 2.93 respectively), and significant binding energy (? Ebind=-21.18 and -23.57kJ/mol respectively) in MMPBSA calculation can be further investigated as lead CAII inhibitors.

Keyword: Carbonic anhydrase II, cardenolides, reverse pharmacophore, uzarigenin, calotropogenin

DOI: https://doi.org/10.31838/ijpr/2020.SP1.054

Download: Request For Article





9/21/2020	ViewSpecialArticleDetail	
		00552809